Literature DB >> 965811

Evidence for cell-mediated immunity to collagen in progressive systemic sclerosis.

J M Stuart, A E Postlethwaite, A H Kang.   

Abstract

Peripheral blood leukocytes from 12 patients with progressive systemic sclerosis and from 12 normal subjects were cultured in the presence of human skin collagen, lathryritic chick skin collagen, and alpha-chains from chick skin collagen. Leukocytes from 11 of the patients produced a factor chemotactic for human monocytes when cultured with the collagen preparations. The one patient whose cells did not respond to the collagen preparations also failed to respond to other common antigens and was apparently anergic. In addition, lymphocytes from three of the patients were found to transform when cultured with the collagen preparations. These responses were significantly different from the response of leukocytes from normal control subjects. The data suggest that patients with progressive systemic sclerosis may have cellular immunity to collagen.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 965811

Source DB:  PubMed          Journal:  J Lab Clin Med        ISSN: 0022-2143


  25 in total

1.  A cell model system to study regulation of phosphotidylinositol 3-kinase and protein kinase B activity by cytokines/growth factors produced by type I collagen stimulated immune cells from patients with systemic sclerosis.

Authors:  Thomas M Chiang; Arnold E Postlethwaite
Journal:  Biochim Biophys Acta       Date:  2007-04-18

Review 2.  Recent advances in the treatment of systemic sclerosis.

Authors:  Vasiliki Kalliopi K Bournia; Panayiotis G Vlachoyiannopoulos; Carlo Selmi; Haralampos M Moutsopoulos; M Eric Gershwin
Journal:  Clin Rev Allergy Immunol       Date:  2009-06       Impact factor: 8.667

3.  A multicenter, randomized, double-blind, placebo-controlled trial of oral type I collagen treatment in patients with diffuse cutaneous systemic sclerosis: I. oral type I collagen does not improve skin in all patients, but may improve skin in late-phase disease.

Authors:  Arnold E Postlethwaite; Weng Kee Wong; Philip Clements; Soumya Chatterjee; Barri J Fessler; Andrew H Kang; Joseph Korn; Maureen Mayes; Peter A Merkel; Jerry A Molitor; Larry Moreland; Naomi Rothfield; Robert W Simms; Edwin A Smith; Robert Spiera; Virginia Steen; Kenneth Warrington; Barbara White; Frederick Wigley; Daniel E Furst
Journal:  Arthritis Rheum       Date:  2008-06

Review 4.  Pathogenesis of Systemic Sclerosis.

Authors:  Debendra Pattanaik; Monica Brown; Bradley C Postlethwaite; Arnold E Postlethwaite
Journal:  Front Immunol       Date:  2015-06-08       Impact factor: 7.561

5.  Cellular sensitivity to collagen in liver disease.

Authors:  H Sawada; T Suou; C Hirayama
Journal:  Clin Exp Immunol       Date:  1985-02       Impact factor: 4.330

6.  Stimulation with type I collagen induces changes in gene expression in peripheral blood mononuclear cells from patients with diffuse cutaneous systemic sclerosis (scleroderma).

Authors:  S P Atamas; I G Luzina; J Ingels; J Choi; W K Wong; D E Furst; P J Clements; A E Postlethwaite
Journal:  Clin Exp Immunol       Date:  2010-09       Impact factor: 4.330

Review 7.  Diseases of the collagen molecule.

Authors:  C I Levene
Journal:  J Clin Pathol Suppl (R Coll Pathol)       Date:  1978

8.  Subpopulations of human T lymphocytes. IX. Imbalance of T cell subpopulations in patients with progressive systemic sclerosis.

Authors:  S Gupta; A N Malaviya; P Rajagopalan; R A Good
Journal:  Clin Exp Immunol       Date:  1979-11       Impact factor: 4.330

9.  Immunohistologic and ultrastructural study of the sclerotic skin in chronic graft-versus-host disease in man.

Authors:  A Janin-Mercier; A Devergie; D Van Cauwenberge; J H Saurat; M Bourges; C M Lapiere; E Gluckman
Journal:  Am J Pathol       Date:  1984-05       Impact factor: 4.307

10.  Lymphocyte subpopulations and reactivity to mitogens in patients with scleroderma.

Authors:  M Baron; E C Keystone; D D Gladman; P Lee; L Poplonski
Journal:  Clin Exp Immunol       Date:  1981-10       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.